R&D channel feed – Endpoints News

R&D channel feed

AstraZeneca jettisons another drug, this time grabbing $30M for out-licensing deal

9 years ago

Hold the applause: Big Pharma has little to brag about regarding 2016 R&D productivity

9 years ago

Novartis unveils a new global R&D structure, creating centers in Cambridge, MA and Basel

9 years ago

Novartis is uprooting another research group in ongoing global reorganization

9 years ago

Hustling to capture top frontline NSCLC status, Roche scores a ‘breakthrough’ on Alecensa

9 years ago

Amgen joins a marquee list of partners jumping on Nuevolution’s discovery platform

9 years ago

Soriot’s $3.5B Brilinta dream is dashed by yet another big trial flop for AstraZeneca

9 years ago

Summit shares rocket up, fueled by an $842M pact with Duchenne leader Sarepta

9 years ago

Sun Pharma takes aim at a crowded market with another IL-23 psoriasis drug from Merck

9 years ago

Merrimack CEO is out as the biotech restructures, chopping its workforce and overhauling R&D

9 years ago

$95M mega-round in hand, Elaine Sullivan sets out to build a European oncology player

9 years ago

AstraZeneca hands off another Amgen-partnered drug in a $1.5B deal with an acquisitive Allergan

9 years ago

J&J’s IL-23 star guselkumab grabs the spotlight in PhIII psoriasis showdown

9 years ago

Blockbuster performance: Regeneron, Sanofi add stellar PhIII dupilumab data on display at EADV

9 years ago

Following lethal tox report, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal

9 years ago

In a setback, Regeneron reports a mid-stage flop for next-gen Eylea combo

9 years ago

ImmunoGen's new CEO retrenches, axing 65 staffers and looking to thin pipeline

9 years ago

Amgen beefs up cardio pipeline, adding a $673M RNAi deal with Arrowhead

9 years ago

Step two: Celgene grabs a $20M option, plots MS PhII for Abide’s cannabinoid drug

9 years ago

Novo Nordisk takes out the ax and aims at R&D, chopping 1,000 jobs

9 years ago

Genentech snares a PhI RAF inhibitor from Hanmi in $910M deal

9 years ago

FDA slaps a full clinical hold on Alcobra’s troubled lead drug for ADHD, Fragile X

9 years ago

Novartis, Amgen rack up their first PhIII success in a crowded CGRP migraine drug field

9 years ago

The 2nd PhIII schizophrenia study for Intra-Cellular drug is a disaster, shares shredded

9 years ago

First page Previous page 317 318 319320321 322 323 Next page Last page